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Purpose: Photon-based radiation therapy does currently not play a major role as local ablative treatment for
hepatocellular carcinoma (HCC). Carbon ions offer distinct physical and biological advantages. Due to their inverted
dose profile and the high local dose deposition within the Bragg peak, precise dose application and sparing of
normal tissue is possible. Furthermore, carbon ions have an increased relative biological effectiveness (RBE)
compared to photons.
Methods and materials: A total of six patients with one or more HCC-lesions were treated with carbon ions
delivered by the raster-scanning technique according to our clinical trial protocol. Diagnosis of HCC was confirmed
by histology or two different imaging modalities (CT and MRI) according to the AASLD-guidelines. Applied
fractionation scheme was 4 × 10 Gy(RBE). Correct dose application was controlled by in-vivo PET measurement of
β + −activity in the irradiated tissue shortly after treatment.
Results: Patients were observed for a median time period of 11.0 months (range, 3.4 – 12.7 months). Imaging
studies showed a partial response in 4/7 lesions and a stable disease in 3/7 lesions in follow-up CT- and MRI scans.
Local control was 100%. One patient with multifocal intrahepatic disease underwent liver transplantation 3 months
after carbon ion therapy. During radiotherapy and the follow-up period no severe adverse events have occurred.
Conclusions: We report the first clinical results of patients with HCC undergoing carbon ion therapy using the
rasterscanning technique at our institution. All patients are locally controlled and experienced no higher toxicities in
a short follow-up period. Further patients will be included in our prospective Phase-I clinical trial PROMETHEUS-01
(NCT01167374).Introduction
Photon-based radiation therapy does currently not play
a major role as local ablative treatment for hepatocellu-
lar carcinoma (HCC). Usually the therapeutic standard is
surgical resection or if not possible local ablative treat-
ments such as transcatheter arterial chemoembolization
(TACE) and radio-frequency-ablation (RFA). Despite* Correspondence: daniel.habermehl@med.uni-heidelberg.de
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distribution, and reproduction in any mediumtechnical improvements in these fields over the last few
years there are still patients not suitable for one of these
treatments, e.g. because of a liver cirrhosis with de-
creased liver function due to locally advanced tumors. If
none of these therapeutic procedures can be applied or
when patients have metastasized disease, standard of
care therapy consists of a systemic treatment with the
multi-kinase inhibitor sorafenib (NexavarW) which leads
to an improvement in overall survival of two months in
locally advanced HCC [1].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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shown to lead to good local control rates in small pa-
tient cohorts but its use is mainly based on an individual
decision making and its application should currently be
designed in clinical trials. One of the most limiting
factors is the relatively low radiation tolerance of nor-
mal liver tissue, thus leading to clinical evaluation of
high precision radiation techniques such as image guid-
ance (IGRT, image-guided radiotherapy) or even particle
beam therapy (PBT), including protons (H1) or carbon
ions (C12) [2]. High doses are required for long-term
control of HCC- lesions but are difficult to apply be-
cause of the limited radiation tolerance of the normal
liver tissue, even with modern EBRT (External Beam Ra-
diation Therapy) techniques [3]. Therefore carbon ions
offer distinct physical and biological advantages. Due to
their inverted dose profile and the high local dose de-
position within the Bragg peak, precise dose application
and sparing of normal tissue is possible. Furthermore,
carbon ions have an increased relative biological effect-
iveness (RBE) compared to photons [4]. A phase-I
clinical trial evaluating toxicity and therapy outcome for
HCC-patients treated with carbon ions was initiated at
our institution. Patients presented in this manuscript
were treated according to the study protocol and re-
ceived a total dose of 4 × 10 Gy(RBE) using carbon ions
at our institution which represent the first dose level
according to the dose escalation study concept.Patients and methods
Patient selection
Patients were selected according to the clinical trial
protocol; main inclusion criteria were histologically con-
firmed HCC or diagnosis of HCC according to AASLD-
guidelines [5] macroscopic tumor, liver-confined disease
without extrahepatic disease as diagnosed by CT, MRI,
ultrasound and bone scan, minimal distance of tumor
edge to the intestines of 1 cm, age ≥ 18 years old and
Karnofsky Performance Score ≥ 60. All patients are seen
and evaluated in an interdisciplinary setting including
specialists from Gastroentereology, Surgery, Radiology
and Radiation Oncology.
A total of six patients (n = 6) with one or more HCC-
lesions (n = 7) were identified and selected for treat-
ment with carbon ions delivered by the raster-scanning
technique at our institution according to our clinical
trial protocol. Diagnosis of HCC was confirmed by
histology or two different imaging modalities (CT and
MRI) according to the AASLD-guidelines. Applied
fractionation scheme was 4 × 10 Gy(RBE). No inter-
ruptions > 4 days during study treatment were allowed.
Median duration of treatment was 9.5 days (range, 8–
11 days).Patient immobilization
Patients were immobilized as described previously [6].
In brief, patients were immobilized using an individually
shaped vacuum pillow and -in most cases- an abdom-
inal compression to reduce the liver movement. A CT
scan was done for treatment planning and the effective-
ness of the abdominal compression was measured. On
the treatment day patients were repositioned in the
above mentioned setting using pen marks and another
control CT scan. If the repositioning was adequate the
patients were carried to the particle-beam treatment
room. One patient received irradiation using respiratory
gating. Daily patient positioning was controlled by the
comparison of treatment planning Digitally Reconstructed
Radiographs (DRRs) with kilovoltage images. Correct dose
application was controlled by in-vivo PET measurement
of β + −activity in the irradiated tissue shortly after the
treatment session correlated with CT scans or in selected
cases with 4D-CT-scans to account for 4D-dose distribu-
tion (Figure 1).Treatment planning
For the first patients undergoing hypofractionated carbon
ion therapy we decided to use the best known and
established immobilization setup since respiratory gating
is not yet established at or institution. Furthermore organ
motion has to be concerned and leads to dose
inhomogenities especially in intensity-modulated radio-
therapy and also in particle radiotherapy using the
rasterscanning technique. Therefore we aimed to
minimize organ and tumor motion to reduce possible
interplay effects and dose inhomogenities. In one patient
we decided to implement respiratory gating. In this pa-
tient a 4D-CT was acquired as previously described. The
different single reconstructed standardized respiration
phases (at least 8 for one breathing cycle: 0%/40%/70%/
100% exspiration and 20%/25%/50%/75% inspiration
phases) were analyzed and a time window was chosen
where organ motion was relatively low, e.g. period be-
tween 70% inspiration and 20% exspiration. We were
carefully in implementing this new technique in the
experimental setup and have therefore chosen to define a
final ITV (internal target volume) that includes the
tumour during the whole respiratory cycle and not only
the tumor in the above mentioned respiratory phase
(period between 70% inspiration and 20% exspiration)
with the idea to cover the tumour irrespective of any
incertainties during the irradiation procedure. Finally we
analyzed the patients’ respiratory curve each treatment
day and decided flexibly the time window for irradiation.
Live representation of the breathing cycles were moni-
tored with a commercial system using a pressure sensor
attached to the waist belt.
TPS dose with PTV PET measurement after RT 
Figure 1 Measurement of β+-activity at a dedicated PET/CT scanner after application of a dose of 10 Gy(RBE). Calculation of dose
distribution with SyngoW RT planning (TPS).
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kidney, spleen and spinal cord were contoured. Dose
constraints of normal tissue were respected according to
Pan et al. [7].
The Gross Tumor Volume (GTV) was defined as the
area of solid macroscopic tumor contrast enhancement on
CT and/or MR-imaging. The Clinical Target Volume
(CTV) was defined as the GTV plus a margin of 5 mm.
The Planning Target Volume (PTV) included the CTV
plus a margin of about 1 cm to account for residual organ
motion (all patients underwent contrast enhanced 4D-CT
for treatment planning) and setup inaccuracies. C12-RT
(carbon ion-radiotherapy) planning was performed using
the treatment planning software “Syngo PT Planning”
developed by Siemens Oncology Care Systems (OCS,
Erlangen, Germany) including biologic plan optimization
and was based on the Local Effect Model (LEM) devel-
oped by GSI (Gesellschaft für Schwerionenforschung); it is
designed for RBE-calculation in different tissue types and
for selected endpoints [8]. The optimization of the beam
control parameters for the raster scanning technique of
the treatment planning system is exerted with respect to
the biological effective dose. Treatment was done using a
fixed right lateral horizontal beam for all patients in the
described time period.
Dose inhomogeneity is a serious topic in scanned
beam particle therapy of moving organs. Our attempts
to minimize the possible dose inhomogeneities were the
use of an abdominal compression to reduce organ and
thus tumor motion, the implementation of respiratory
gating in one patient, the verification of each treatment
plan before definitive treatment and post-treatment 4D
dose reconstruction (nota bene in addition to the autoactivation imaging). Nevertheless, a recent analysis of
the described patients of Richter D. and collegues from
our institution (‘4D treatment dose reconstruction for
scanned ion beam therapy’, abstract submitted to
ASTRO Annual Meeting 2013) revealed a considerable
impact of interplay effects on single fraction CTV dose.
However, the observed inhomogeneities were clearly re-
duced for the total applied dose due to the fractionated
treatment.
Follow-up
Patients are currently undergoing follow-up visits with
physical examination, laboratory tests and CT-/MRI-scans
every four weeks during the first three months and every
three months thereafter. Local control (LC) was deter-
mined as time period between the first day of radiotherapy
and appearance of any local recurrence or progression.
Observed toxicity was categorized according to the Com-
mon Toxicity Criteria of Adverse Events version 4.03.
Treatment response
Treatment response was measured and classified as pro-
posed by the AASLD Panel of Experts in HCC-Design
Clinical Trials criteria 2008 [9]:
– Complete response (CR): disappearance of any intra-
tumor arterial enhancement in all target lesions.
– Partial response (PR): at least a 30% decrease in the
sum of diameters of the target lesions.
– Progressive disease (PD): increase of at least 20%
increase in the sum of diameters of target lesions
referred to the smallest sum of the diameters of
viable target lesions recorded since start of
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lesions as per RECIST.
– Stable disease (SD) any cases that do not qualify for
either PR or PD.
Ethical approval
The procedures set out in this trial protocol will be
performed according to Good Clinical Practice (GCP)
and the ethical principles described in the applicable
version of the Declaration of Helsinki (2008 Version of
the Declaration of Helsinki, adopted at the 59th WMA
General Assembly, Seoul, October 2008). The trial will
be carried out in keeping with local legal and regulatory
requirements. The study plan was submitted to the
Institutional Review Board (IRB)/independent Ethics
Committee (EC) of the Medical Faculty Heidelberg for
approval. Approval of the Bundesamt für Strahlenschutz
(BfS) was obtained prior to enrolment into the trial.
Results
Local control and survival
Patients were observed for a median follow-up period of
11.0 months (range 3.4–12.7 months). Mean overall sur-
vival was 11 months (range 4.0-12.7 months), and only
one patient died during follow-up because of a worsening
of the underlying liver cirrhosis while the irradiated lesion
was stable.
Imaging studies based on CT and MRI showed a par-
tial response in 4/7 lesions and a stable disease in 3/7
lesions during follow-up. Median time of local control
was 11.3 months (range 2.7-11.9 months) without a
local progression of any treated lesion so far (Figure 2a
and b). One patient with multiple HCC-lesions had a
progression of the non-irradiated lesions after C12-RT
and underwent liver transplantation three months after
therapy which was initially intended as a bridging ther-
apy (Table 1, patient No. 5). This patient started treat-
ment with Sorafenib (NexavarW) at time of disease
progression (of the non-irradiated lesions).
One patient had two HCC-lesions at time of C12-RT
(Table 1, patient No. 6). One of these lesions was heavily
pre-treated with repeated PEI (Percutaneous Ethanol
Injection) and TACE and the reason for further treatment
was a recurrent tumor. The non-irradiated and non-
pre-treated lesion was treated four weeks after the end of
RT within a first TACE cycle. Child-Pugh-score of this
patient was CHILD B and already before initiation of RT
hospitalization was needed because of a deterioration of
the hepatic encephalopathy (HE). The patient died four
months after repeated periods of HE.
The clinical target volume (CTV) of the second patient
with a radiological diagnosed recurrence of a previously
treated HCC lesion (12 months before) included a
suspected residual fibrotic region in which proximitythe recurrent tumor was located (Table 1, patient
No. 2). This patient had a fulminant intrahepatic progres-
sion 10 months after C12-RT with multiple new lesions
and newly diagnosed synchronous bone metastases, but
the irradiated lesion was controlled.
Toxicity
Overall tolerance of treatment was well. Five of six pa-
tients (83%) reported mild fatigue symptoms. During
follow-up none of the patients reported new symptoms.
During radiotherapy and the current follow-up period
no severe adverse events have occurred. One patient had
hepatic encephalopathy and ascites at start of RT and
was treated with TACE of a second lesion four weeks
after RT, so possible adverse events cannot clearly be
assigned to one specific treatment. Subclinical elevations
of liver parameters such as ALA, GGT, AP and bilirubin
were observed but were almost grade I-II (Table 2).
None of the patients had grade-IV or –V toxicities
during follow-up.
Discussion
Particle therapy delivered as carbon ion therapy using
the rasterscanning technique at our institution offers a
promising treatment opportunity for patients with both
recurrent and primary HCC. Our early results on
hypofractionated carbon ion therapy for this indication
prove an effective local ablative treatment with a good
tolerability. It presents for the first time a radical
hypofractionated therapy with local ablative doses using
this radiation technique. None of the treated patients
experienced a local recurrence during follow-up in
addition to a complete absence of any higher grade tox-
icity (grade IV-V according to CTCAE 4.03). In sum-
mary the presented outcome is comparable to previous
published series on carbon ion therapy from japanese
institutions [2,10].
Results of an early dose-escalation clinical trial from
Kato and colleagues were promising with local control
rates of more than 90% one year after therapy in 24 pa-
tients [10]. The dose-concept consisted of 15 fractions
delivered in increasing single doses and starting with an
overall dose of 49.5 Gy(RBE). The highest applied dose
was 79.5 Gy(RBE). In 71% of all cases tumor response
was seen local control rates were 92%, 81% and 81%
after 1, 3 and 5 years. No dose-limiting side effects
appeared. The authors finally suggest an overall dose of
72 Gy(RBE) to have an optimal gain between high local
tumor control and low probability of grade III toxicities.
Until now there is still an apparent lack of prospective
studies on particle therapy for HCC: Current treatment
recommendations are based on (partially large) retrospect-
ive cohort analyses from japanese institutions. A recent
study of Komatsu and colleagues reports on 343 patients
initial 4 weeks after RT
8 weeks after RT 12 weeks after RT
initial 4 weeks after RT 12 weeks after RT
b
a
Figure 2 (a). Treatment response after carbon ion irradiation of a HCC lesion after 4, 8 and 12 weeks (contrast enhanced MRI). Perifocal
contrast enhancement indicates radiation-induced liver reaction. (b). Treatment response of the same patient after 4 and 12 weeks (contrast
enhanced CT).
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lesions) or carbon ion therapy (101 patients, 108 lesions)
[2]. Carbon ion therapy consisted of 4 different protocols
in which 4–20 fractions were applied, with overall doses
of 52.8-76 Gy(RBE). Local control rate and overall survival
were 93% and 36.3% respectively after a follow-up of
5 years. Multivariate analyses revealed tumor size as the
only independent risk factor for a local failure. No higher
therapy-related toxicity was observed.In a recent retrospective analysis Imada et al. analyzed
treatment outcome after C12-RT for 18 patients with
tumors in proximity of the porta hepatis [11]. This group
of patients is of special interest because complication rates
are comparably high when standard therapeutic proce-
dures are applied (proximity to large vessels and common
hepatic duct). The authors could show that local control
after short-course C12-RT of 4 fractions and a total dose
of 52.8 Gy(RBE) delivered during 1 week was as high as in





















1 F 78 1 1 4.5 none yes 9.4 10.7 PR History of breast cancer and stroke, diabetes mell. type II PROMETHEUS





11.3 11.3 SD History of metastasized seminoma, AL-amyloidosis type
lambda, MALT-lymphoma of the lung, cardiomyopathy,
coronary heart disease, diabetes mell. Type II
3 M 67 1 1 3.3 none No, CT +
MRI
11.8 12.7 PR diabetes mell. type II, myasthenia gravis, congestive heart
failure
4 F 78 2 2 3.7 and
0.9
none Yes 11.9 11.9 PR diabetes mell. type II, COPD II°
5 M 53 multiple 1 4.0 none Yes 3.4 3.4 SD History of renal cell carcinoma, cardiomyopathy, coronary















F = female, M = male, CT = computed tomography, MRI = magnetic resonance imaging, LC = local control, OS = overall survival, PR = partial remission, SD = stable disease, RT = radiotherapy, PEI = percutaneous

















Table 2 Patient and treatment details



















Prior treatment of irradiated lesion(s)
Yes 2
No 4
Tumor size [cm] (median, range) 3.5 (0.9 – 4.5)













Duration of RT (median, range) [days] 9.5 (8–11)
RT Radiotherapy, Gy Gray.
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porta (5-year-LC of 87.8% and 95.7% for tumors in the
near of the porta hepatis and others, respectively).
Concerning the clinical evidence for the use of par-
ticle therapy it has to be remarked that there are cur-
rently more significant results derived from proton
therapy studies. There are at least three mono-
institutional phase-II-studies [12,13]: Patient numbers
range from 27 to 75 and the median tumour size ranges
from 2.8-5.5 cm. Most patients had underlying liver
cirrhosis. The applied hypofractionation protocols are
differing and consisted of 15 × 4.2 Gy(RBE) (total 63 Gy
(RBE) ) 20 × 3.8 Gy(RBE) (total 76 Gy(RBE) ) [14]. Ther-
apy was overall well tolerated in all three reports and
only few grade-III toxicities occurred. Bush et al. report
a median PFS of 36 months and a local control rate of
60% after 3 years [12,14]. Eighteen patients benefit from
irradiation and underwent liver transplantation during
follow-up. In a previous study from the same institution
only 1 local relapse occurred after a median follow-up
of 31 months and 2-year PFS was as high as 96%.
After C12-RT characteristic morphological changes
were observed in the irradiated liver regions and mainly
consisted of an increased contrast agent uptake around
the target lesions. These phenomena are known from
photon-based radiosurgery of liver tumors and are due
to well-defined histological changes resembling a focal
veno-occlusive disease and its consecutive impact on
contrast agent dynamics [15,16]. A detailed analysis of
these radiological findings related to C12-RT is in prep-
aration and will be discussed elsewhere.
In comparison to other local ablative therapies such
as partial or hemi-hepatectomy or RFA and TACE, out-
come of C12-RT does not seem to be inferior to these
established treatments and can also be applied in pa-
tients with unfavorable factors such as a low perform-
ance state, large tumor size, tumor location in proximity
to large vessels, severe co-morbidities and a decreased
liver function. Nevertheless, the latter factor has to be
considered with caution because previous reports point
to a possible hepatic impairment after particle therapy,
even though no reliable constraints and dose-volume
specifications can be defined so far, especially for
C12-RT [17]. We observed no severe treatment-related
toxicities, especially no clinical relevant signs beside
mild fatigue symptoms. In some patients liver enzymes
increased with time but it remains unclear if all eleva-
tions are uniquely due to C12-RT or to a temporarily
decreased hepatic function in the course of the under-
lying liver disease (liver cirrhosis). Beside, it has to be
highlighted that in treated cirrhotic patients the under-
lying cirrhosis was certainly alcohol-induced whereas
cirrhotic Asian patients with the same diagnosis rather
have a history of hepatitis.Our study confirms for the first time the impressive re-
sults from our Japanese colleagues. Furthermore the
rasterscanning method of beam delivery offers advantages
compared to the passive beam delivery technique at the
centers in Japan. The delivery of passive beams requires
patient-specific beam-modifying devices to achieve an
adequate dose distribution to the target structures, which
is theoretically associated with a prolonged setup and
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bution is not always optimal. On the other hand a scan-
ning beam allows improved target volume coverage and
sparing of surrounding (normal) tissue. Despite the obvi-
ous advantages of scanned beams, moving targets (i.e. the
liver) remain a crucial issue because of an increased risk
of target misses and misdosage of the target volume due
to intra-fractional motion. Compensatory mechanisms
include therefore adapted target margins (4D-CT, ITV)
and the new implemented respiratory gating [18]. The
latter issue is of high importance for the future treatment
of our HCC patients and has still to be optimized in
cooperation with our colleagues from GSI (Darmstadt).
A further limitation is the fixed 90° horizontal beam
line which only allows radiation fields from the right lat-
eral side. All patients have been treated with a single
scanned ion beam and dose distribution was acceptable
in all cases. Until our 360° gantry for particle beams is in
operation – thus improving our beam angle options – the
fixed single beam line will be in use.
For the first time we present the feasibility and efficacy of
a hypofractionated carbon ion therapy for primary and re-
current HCC delivered with the rasterscanning technique.
The complex workflow including patient immobilization,
image-guidance, respiratory gating and active scanning
beam delivery were successfully implemented at our institu-
tion. All patients are locally controlled and experienced no
higher toxicities.
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